<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-9957</journal-id>
<journal-title><![CDATA[Revista colombiana de Gastroenterología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. Gastroenterol.]]></abbrev-journal-title>
<issn>0120-9957</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Gastroenterología  ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-99572025000400441</article-id>
<article-id pub-id-type="doi">10.22516/25007440.1381</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Effect of Rifaximin on Quality of Life in Patients with Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth]]></article-title>
<article-title xml:lang="es"><![CDATA[Efecto de la rifaximina sobre la calidad de vida en síndrome de intestino irritable con sobrecrecimiento bacteriano]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Sampayo]]></surname>
<given-names><![CDATA[Faruk]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Yepes-Barreto]]></surname>
<given-names><![CDATA[Ismael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-del Risco]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Cartagena  ]]></institution>
<addr-line><![CDATA[Cartagena ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Biomedical Sciences  ]]></institution>
<addr-line><![CDATA[Cartagena ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Cartagena  ]]></institution>
<addr-line><![CDATA[Cartagena ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>40</volume>
<numero>4</numero>
<fpage>441</fpage>
<lpage>449</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-99572025000400441&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-99572025000400441&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-99572025000400441&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder with a multifactorial pathophysiology, including alterations in the gut microbiota. Small intestinal bacterial overgrowth (SIBO) may coexist with IBS and exacerbate symptoms, adversely affecting quality of life.  Objective:  To evaluate the impact of rifaximin therapy on quality of life in patients diagnosed with IBS and SIBO, using the validated IBS-QoL instrument and Rome IV criteria.  Methods: A quasi-experimental study was conducted at a gastroenterology center in Cartagena, Colombia, between June 2023 and January 2024. Patients with IBS diagnosed through Rome IV criteria and a positive breath test for SIBO were included. Participants received rifaximin 550 mg every 8 hours for 14 days. Quality of life was assessed before and after treatment using the IBS-QoL scale.  Results: Seventy-one patients with confirmed SIBO were enrolled. The mean age was 48.6 years, and 81.8% were women. Following treatment, a significant improvement in quality-of-life scores was observed (p &lt;0.001), along with a reduction in major symptoms-particularly abdominal distension, bloating, and flatulence. A total of 26.7% of participants reported no improvement.  Conclusion: The study suggests that rifaximin therapy is associated with symptomatic improvement and enhanced quality of life among patients with IBS and SIBO, with the greatest benefit observed in those presenting with abdominal distension.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: El síndrome de intestino irritable (SII) es un trastorno gastrointestinal crónico cuya fisiopatología involucra múltiples factores, incluida la alteración del microbiota intestinal. El sobrecrecimiento bacteriano del intestino delgado (SIBO) puede coexistir con el SII y agravar sus síntomas, lo que afecta negativamente la calidad de vida.  Objetivo: Evaluar el impacto del tratamiento con rifaximina sobre la calidad de vida de pacientes con diagnóstico de SII y SIBO, utilizando la escala validada IBS-QoL y los criterios de Roma IV.  Metodología:  Estudio cuasiexperimental realizado en un centro de gastroenterología en Cartagena, Colombia, entre junio de 2023 y enero de 2024. Se incluyeron pacientes diagnosticados con SII según los criterios de Roma IV con una prueba de aliento positiva para SIBO. Recibieron rifaximina 550 mg cada 8 horas durante 14 días. La calidad de vida se evaluó antes y después del tratamiento con la escala IBS-QoL.  Resultados:  Participaron 71 pacientes con diagnóstico confirmado de SIBO. La media de edad fue de 48,6 años y el 81,8% fueron mujeres. Después del tratamiento, se observó una mejoría significativa en la calidad de vida (p &lt;0,001) y en los síntomas principales, especialmente distensión abdominal, hinchazón y flatulencias. Un 26,7% de los pacientes no mostró mejoría.  Conclusión:  El presente estudio sugiere que el tratamiento con rifaximina se asocia a una mejoría sintomática y en la calidad de vida en pacientes con SII y SIBO, particularmente en aquellos con distensión abdominal.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Irritable bowel syndrome]]></kwd>
<kwd lng="en"><![CDATA[intestine]]></kwd>
<kwd lng="en"><![CDATA[quality of life]]></kwd>
<kwd lng="en"><![CDATA[microbiota]]></kwd>
<kwd lng="es"><![CDATA[Síndrome de intestino irritable]]></kwd>
<kwd lng="es"><![CDATA[intestino]]></kwd>
<kwd lng="es"><![CDATA[calidad de vida]]></kwd>
<kwd lng="es"><![CDATA[microbiota]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pontet]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Olano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de síndrome de intestino irritable en América Latina]]></article-title>
<source><![CDATA[Revista de Gastroenterología del Perú]]></source>
<year>2021</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>144-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmulson]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Puentes-Leal]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Bustos-Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Francisconi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López-Colombo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the epidemiology of disorders of gut-brain interaction in four Latin American countries: Results of The Rome Foundation Global Epidemiology Study]]></article-title>
<source><![CDATA[Neurogastroenterol Motil]]></source>
<year>2023</year>
<volume>35</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Álvarez]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Morales-Vargas]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas-Medina]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Mújica-Oviedo]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Camacho-López]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Rueda-Jaimes]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores sociosanitarios y prevalencia del síndrome del intestino irritable según los criterios diagnósticos de Roma III en una población general de Colombia]]></article-title>
<source><![CDATA[Gastroenterol Hepatol]]></source>
<year>2009</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>395-400</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scarpellini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Giorgio]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gabrielli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lauritano]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Pantanella]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fundarò]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>2009</year>
<volume>155</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>416-20</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sperber]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Bangdiwala]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Drossman]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Ghoshal]]></surname>
<given-names><![CDATA[UC]]></given-names>
</name>
<name>
<surname><![CDATA[Simren]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tack]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Worldwide prevalence and burden of functional gastrointestinal disorders: results of the Rome Foundation Global Study]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2021</year>
<volume>160</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>99-114.e3</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bourlioux]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Braesco]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Koletzko]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Guarner]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The intestine and its microflora are partners for the protection of the host]]></article-title>
<source><![CDATA[Am J Clin Nutr]]></source>
<year>2003</year>
<numero>78</numero>
<issue>78</issue>
<page-range>675-83</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tojo González]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Suarez Gonzalez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rúas Madiedo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mancebo Mata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pipa Muñiz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barreiro Alonso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de intestino irritable: papel de la microbiota y probiótico-terapia]]></article-title>
<source><![CDATA[Nutr Hosp]]></source>
<year>2015</year>
<volume>31</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>83-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Talley]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kendall]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Koloski]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2020</year>
<volume>115</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>190-201</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mishima]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ishihara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular mechanisms of microbiota-mediated pathology in irritable bowel syndrome]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2020</year>
<volume>21</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>8664</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takakura]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Pimentel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Small intestinal bacterial overgrowth and irritable bowel syndrome: an update]]></article-title>
<source><![CDATA[Front Psychiatry]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>664</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pimentel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[SSC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ACG clinical guideline: small intestinal bacterial overgrowth]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2020</year>
<volume>115</volume>
<page-range>165-78</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Quigley]]></surname>
<given-names><![CDATA[EMM]]></given-names>
</name>
<name>
<surname><![CDATA[Madrid]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobrecrecimiento bacteriano intestinal: artículo de revisión]]></article-title>
<source><![CDATA[Rev Med Chile]]></source>
<year>2005</year>
<volume>133</volume>
<page-range>1361-70</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blasco-Alonso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Torcuato Rubio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pueyo Agudo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Polo Hernández]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz Pérez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martín Masot]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnóstico de sobrecrecimiento bacteriano mediante empleo de prueba de hidrógeno espirado en niños afectos de síndrome de intestino irritable]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Álvarez Calatayud]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Barros García]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco Rodríguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Blasco Alonso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bodas Pinedo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Camarena Grande]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<source><![CDATA[). Libro de Trabajos SEGHNP 2020]]></source>
<year>2020</year>
<page-range>112</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ergon]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giannella]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Rout]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Toskes]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Jejunal brush border injury and impaired sugar and amino acid uptake in the blind loop syndrome]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>1974</year>
<numero>67</numero>
<issue>67</issue>
<page-range>965-74</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avelar-Rodríguez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Toro-Monjaraz]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Mayans]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobrecrecimiento bacteriano en el intestino delgado: una causa de dolor abdominal crónico en niños]]></article-title>
<source><![CDATA[Bol Med Hosp Infant Mex]]></source>
<year>2019</year>
<volume>40</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>93-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tuteja]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Talley]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stoddard]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Verne]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Double-blind placebo-controlled study of rifaximin and lactulose hydrogen breath test in Gulf War veterans with irritable bowel syndrome]]></article-title>
<source><![CDATA[Dig Dis Sci]]></source>
<year>2019</year>
<volume>64</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>838-45</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>Dolopedia</collab>
<source><![CDATA[Escalas unidimensionales del dolor]]></source>
<year>2024</year>
<publisher-name><![CDATA[Dolopedia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarado-Bestene]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Varón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cáceres-Méndez]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto en la calidad de vida por la asociación entre trastornos del sueño y síndrome de intestino irritable]]></article-title>
<source><![CDATA[Rev Colomb Gastroenterol]]></source>
<year>2016</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castañeda-Sepúlveda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Irritable bowel syndrome]]></article-title>
<source><![CDATA[Med Univ (Méx)]]></source>
<year>2010</year>
<volume>12</volume>
<numero>46</numero>
<issue>46</issue>
<page-range>39-46</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<collab>WHOQOL Group</collab>
<article-title xml:lang=""><![CDATA[The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization]]></article-title>
<source><![CDATA[Soc Sci Med]]></source>
<year>1995</year>
<volume>41</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1403-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[ZJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Duan]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of rifaximin]]></article-title>
<source><![CDATA[Zhonghua Yi Xue Za Zhi]]></source>
<year>2016</year>
<volume>96</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>1896-902</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Irineo]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calidad de vida relacionada con la salud en adultos con síndrome de intestino irritable en un hospital de especialidades de México: estudio transversal]]></article-title>
<source><![CDATA[Rev Esp Enferm Dig]]></source>
<year>2017</year>
<volume>109</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>265-72</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yepes]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Múnera]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Martelo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dieta baja en oligosacáridos, disacáridos, monosacáridos y polioles fermentables y calidad de vida en pacientes con síndrome de intestino irritable en Colombia]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2018</year>
<volume>38</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>54-61</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
